Clinical trial · Interventional
[18F]FPIA PET/CT Imaging in Patients With Solid Tumours
An Investigation of Short-chain Fatty Acid Uptake in Solid Tumours as Assessed by [18F]Fluoropivalate Positron Emission Tomography and Its Relationship With Tumour Proliferation
NCT04717674CI-TRIAL-00070136[18F]FPIAunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study will be a phase 2, open-label study in patients with solid tumours to explore the relationship between short-chain fatty acid uptake using \[18F\]FPIA PET/CT and tumour proliferation
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Tumor, Solid | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) | Drug | — | UNRESOLVED |
| PET/CT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Drug: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA)
- description
- Participants will undergo two PET/CT scans with the tracer \[18F\]Fluoropivalate (\[18F\]Fluoro-2,2-Dimethylpropionic Acid) (FPIA), referred to as \[18F\]FPIA, on 2 separate visits.
- interventionNames
- Drug: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)
- Procedure: PET/CT
Primary outcomes (1)
- measure
- The relationship between [18F]FPIA uptake and percent positive tumour cells reported as counts defined per area from whole section immunohistochemistry for PHH3.
- timeFrame
- 6 months
- description
- To explore the relationship between short-chain fatty acid uptake using \[18F\]FPIA PET/CT and tumour proliferation in patients with solid tumours.
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with radiological evidence of solid primary or metastatic target tumour lesions and the following characteristics will be recruited: 1. Age ≥18 years of age 2. Radiologically confirmed tumour size ≥15mm (at least one lesion must be extra-hepatic) 3. The participant is due to undergo surgery within 3 months of the first \[18F\]FPIA PET/CT 4. There is time to complete the two research PET studies without any delay to surgery 5. WHO performance status 0 -2 6. If female, the participant is either post-menopausal (\>1 year), or surgically sterilised (has had a documented bilateral oophorectomy and/or documented hysterectomy, \>2 years), or if of childbearing potential, must have a negative urine pregnancy test within 2 hours prior to injection of imaging agent 7. The participant is able and willing to comply with study procedures, and signed and dated informed consent is obtained. 8. eGFR of ≥30 within 3 months of \[18F\]FPIA injection. 9. The participant is not scheduled to start cancer treatment (e.g. chemotherapy, radiotherapy, biological therapy or immunotherapy) within the study scanning period. Exclusion Criteria: * 1\. The participant has received chemotherapy, immunotherapy, biologic therapy or investigational therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of \[18F\]FPIA injection or is due neoadjuvant therapy between the PET and surgery. 2\. The participant is pregnant or lactating. 3. The participant is scheduled to have a nuclear medicine or contrast scan within 24 hours before the administration of \[18F\]FPIA. 4\. Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure.
References
Publications (0)
Data not yet available
No reference posted for this study.